Volatile Valeant Substitutes Schiller For Ailing CEO
This article was originally published in Scrip
Executive Summary
With investors growing increasingly edgy over the lingering absence of Valeant Pharmaceuticals International Inc.'s ailing chairman and CEO Michael Pearson – whose hospitalization late last month due to severe pneumonia came in the midst of the company's struggle to rebuild its image after being mired in a scandal over its business practices – the firm's board on Jan. 6 appointed former chief financial officer Howard Schiller to take the helm in the interim.